Last updated on March 2020

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Brief description of study

This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe AD.

Detailed Study Description

All subjects will receive a SC dose of either investigational product or placebo as the first dose on day 1.

Subjects who are determined to be non-responders in Part A will receive tezepelumab SC Q2W following completion of all week 16 study activities. Nonresponders are defined as those subjects who have not achieved at least a 50% improvement in EASI at week 16 compared to baseline (day 1).

Safety follow-up is 12 weeks after the EOT visit (14 weeks after the final dose of investigational product).

Clinical Study Identifier: NCT03809663

Find a site near you

Start Over

Research Site

Shinagawa-ku, Japan
  Connect »

Research Site

Chiyoda-ku, Japan
  Connect »

Research Site

Shinjuku-ku, Japan
  Connect »